These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 31771862)
1. Strengthening national teams of experts to support HPV vaccine introduction in Eastern Mediterranean countries: Lessons learnt and recommendations from an international workshop. Dochez C; Al Awaidy S; Mohsni E; Fahmy K; Bouskraoui M Vaccine; 2020 Jan; 38(5):1114-1119. PubMed ID: 31771862 [TBL] [Abstract][Full Text] [Related]
2. Lessons learnt during the national introduction of human papillomavirus (HPV) vaccination programmes in 6 African countries: Stakeholders' perspectives. Abdullahi LH; Hussey GD; Wiysonge CS; Kagina BM S Afr Med J; 2020 May; 110(6):525-531. PubMed ID: 32880566 [TBL] [Abstract][Full Text] [Related]
3. Introduction of human papillomavirus (HPV) vaccination into national immunisation schedules in Europe: Results of the VENICE 2007 survey. King LA; Lévy-Bruhl D; O'Flanagan D; Bacci S; Lopalco PL; Kudjawu Y; Salmaso S; Euro Surveill; 2008 Aug; 13(33):. PubMed ID: 18761891 [TBL] [Abstract][Full Text] [Related]
4. Improving skills and institutional capacity to strengthen adolescent immunisation programmes and health systems in African countries through HPV vaccine introduction. Dochez C; Burnett RJ; Mbassi SM; Were F; Musyoki A; Trovoada D; Mphahlele MJ Papillomavirus Res; 2017 Dec; 4():66-71. PubMed ID: 29179872 [TBL] [Abstract][Full Text] [Related]
5. Human papillomavirus vaccine introduction--the first five years. Markowitz LE; Tsu V; Deeks SL; Cubie H; Wang SA; Vicari AS; Brotherton JM Vaccine; 2012 Nov; 30 Suppl 5():F139-48. PubMed ID: 23199957 [TBL] [Abstract][Full Text] [Related]
6. Prospects and challenges in the introduction of human papillomavirus vaccines in the extended Middle East and North Africa region. Jumaan AO; Ghanem S; Taher J; Braikat M; Al Awaidy S; Dbaibo GS Vaccine; 2013 Dec; 31 Suppl 6():G58-64. PubMed ID: 24331821 [TBL] [Abstract][Full Text] [Related]
7. Human papillomavirus (HPV) vaccination: from clinical studies to immunization programs. Murillo R; Ordóñez-Reyes C Int J Gynecol Cancer; 2019 Oct; 29(8):1317-1326. PubMed ID: 31455660 [TBL] [Abstract][Full Text] [Related]
8. The current state of introduction of HPV vaccination into national immunisation schedules in Europe: results of the VENICE 2008 survey. Lévy-Bruhl D; Bousquet V; King LA; O'Flanagan D; Bacci S; Lopalco PL; Salmaso S; Eur J Cancer; 2009 Oct; 45(15):2709-13. PubMed ID: 19695863 [TBL] [Abstract][Full Text] [Related]
9. Supporting countries in establishing and strengthening NITAGs: lessons learned from 5 years of the SIVAC initiative. Adjagba A; Senouci K; Biellik R; Batmunkh N; Faye PC; Durupt A; Gessner BD; da Silva A Vaccine; 2015 Jan; 33(5):588-95. PubMed ID: 25545597 [TBL] [Abstract][Full Text] [Related]
10. What works for human papillomavirus vaccine introduction in low and middle-income countries? Howard N; Gallagher KE; Mounier-Jack S; Burchett HED; Kabakama S; LaMontagne DS; Watson-Jones D Papillomavirus Res; 2017 Dec; 4():22-25. PubMed ID: 29179865 [TBL] [Abstract][Full Text] [Related]
11. The current state of introduction of human papillomavirus vaccination into national immunisation schedules in Europe: first results of the VENICE2 2010 survey. Dorleans F; Giambi C; Dematte L; Cotter S; Stefanoff P; Mereckiene J; O'Flanagan D; Lopalco PL; D'Ancona F; Levy-Bruhl D; Euro Surveill; 2010 Nov; 15(47):. PubMed ID: 21144444 [TBL] [Abstract][Full Text] [Related]
12. Human papillomavirus (HPV) vaccine coverage achievements in low and middle-income countries 2007-2016. Gallagher KE; Howard N; Kabakama S; Mounier-Jack S; Burchett HED; LaMontagne DS; Watson-Jones D Papillomavirus Res; 2017 Dec; 4():72-78. PubMed ID: 29179873 [TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras. Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157 [TBL] [Abstract][Full Text] [Related]
14. A Meta-Analysis on Human Papillomavirus Type Distribution among Women with Cervical Neoplasia in the WHO Eastern Mediterranean Region. Shoja Z; Farahmand M; Hosseini N; Jalilvand S Intervirology; 2019; 62(3-4):101-111. PubMed ID: 31527382 [TBL] [Abstract][Full Text] [Related]
15. Supporting national immunization technical advisory groups (NITAGs) in resource-constrained settings. New strategies and lessons learned from the Task Force for Global Health's Partnership for influenza vaccine introduction. Ba-Nguz A; Shah A; Bresee JS; Lafond KE; Cavallaro K; Shefer A; Donadel M; Seward JF Vaccine; 2019 Jun; 37(28):3646-3653. PubMed ID: 31130258 [TBL] [Abstract][Full Text] [Related]
16. Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006-January 2008. Koulova A; Tsui J; Irwin K; Van Damme P; Biellik R; Aguado MT Vaccine; 2008 Dec; 26(51):6529-41. PubMed ID: 18805453 [TBL] [Abstract][Full Text] [Related]
17. Global implementation of human papillomavirus (HPV) vaccine: lessons from hepatitis B vaccine. Kane MA Gynecol Oncol; 2010 May; 117(2 Suppl):S32-5. PubMed ID: 20129654 [TBL] [Abstract][Full Text] [Related]
18. Implementation of a national school-based Human Papillomavirus (HPV) vaccine campaign in Fiji: knowledge, vaccine acceptability and information needs of parents. La Vincente SF; Mielnik D; Jenkins K; Bingwor F; Volavola L; Marshall H; Druavesi P; Russell FM; Lokuge K; Mulholland EK BMC Public Health; 2015 Dec; 15():1257. PubMed ID: 26684658 [TBL] [Abstract][Full Text] [Related]
19. Human papillomavirus (HPV) vaccine implementation in low and middle-income countries (LMICs): health system experiences and prospects. Wigle J; Coast E; Watson-Jones D Vaccine; 2013 Aug; 31(37):3811-7. PubMed ID: 23777956 [TBL] [Abstract][Full Text] [Related]
20. Vaccine programme stakeholder perspectives on a hypothetical single-dose human papillomavirus (HPV) vaccine schedule in low and middle-income countries. Gallagher KE; Kelly H; Cocks N; Dixon S; Mounier-Jack S; Howard N; Watson-Jones D Papillomavirus Res; 2018 Dec; 6():33-40. PubMed ID: 30352297 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]